# A Study Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer

> **NCT06614192** · PHASE3 · RECRUITING · sponsor: **AbbVie** · enrollment: 460 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Telisotuzumab Adizutecan
- **DRUG:** Trifluridine/Tipiracil
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT06614192
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-08
- **Primary completion:** 2028-10
- **Final completion:** 2028-10
- **Target enrollment:** 460 (ESTIMATED)
- **Last updated:** 2025-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06614192

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06614192, "A Study Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer". Retrieved via MORVS 2026-10-17 from https://api.morvs.ai/clinical/NCT06614192. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*